

Supplementary Information for:  
**MOTS-c is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis**

**Authors:** Joseph C. Reynolds<sup>1</sup>, Rochelle W. Lai<sup>1</sup>, Jonathan S.T. Woodhead<sup>2,3</sup>, James H. Joly<sup>4</sup>, Cameron J. Mitchell<sup>5,6</sup>, David Cameron-Smith<sup>5</sup>, Ryan Lu<sup>1</sup>, Pinchas Cohen<sup>1,7</sup>, Nicholas A. Graham<sup>4,7</sup>, Bérénice A. Benayoun<sup>1,7,8</sup>, Troy L. Merry<sup>5,6</sup>, Changhan Lee<sup>1,7,9\*</sup>.

<sup>1</sup> Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089.

<sup>2</sup> Discipline of Nutrition, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.

<sup>3</sup> Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.

<sup>4</sup> USC Mork Family Department of Chemical Engineering and Materials Science, Los Angeles, CA 90089.

<sup>5</sup> Liggins Institute, The University of Auckland, Auckland, New Zealand.

<sup>6</sup> School of Kinesiology, University of British Columbia, Vancouver, BC, Canada V6T 1Z3.


<sup>7</sup> USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089.

<sup>8</sup> USC Stem Cell Initiative, Los Angeles, CA 90089.

<sup>9</sup> Biomedical Science, Graduate School, Ajou University, Suwon 16499, Korea.


\*corresponding author: changhan.lee@usc.edu

This file includes Supplementary Figures 1-18.




**Supplementary Figure 1. Absolute MOTS-c levels in human muscle and plasma.**


Relative MOTS-c levels are shown in Fig. 1c-d. Here, the absolute quantification of MOTS-c levels measured by **a** Western blotting on human skeletal muscle collected pre-, post-exercise and 4-hours of resting, normalized to corresponding GAPDH levels (MOTS-c/GAPDH) ( $P=0.0098$ ) and **b** ELISA on plasma from the same individuals collected pre-, mid-, post-exercise and 4-hours of resting ( $n=10$ ) ( $P=0.0011$  Mid-;  $P=0.0020$  Post-exercise). Data are presented as both average values and individual datapoints. Statistics by Wilcoxon matched-pair signed rank test. \* $P<0.005$  \*\* $P<0.01$ .




**Supplementary Figure 2. Rotarod, grip strength, and Barnes Maze tests in MOTS-c treated old mice.** **a** Summary of latency time to fall on the Rotarod test (n=13 Control, n=16 MOTS-c) ( $P=0.0042$ ). The speed of the rotations increased from a starting speed of 24 rpm by 1 rpm every 10 seconds. **b** Grip strength test (n=5) ( $P=0.7012$ ). **c,d** Barnes Maze performance in control and MOTS-c treated 12-week old mice (n=15). **c** There was no change in the average time to find the escape box (latency) between control and MOTS-c treated mice. **d** There was no change in the number of errors made prior to discovering the escape box between groups. Errors were defined as nose-pokes or head deflections over false holes. Data expressed as mean  $\pm$  SEM of three 24-hour acquisition cycles. Two-sided Student's t-test. \* $P<0.05$ . \*\* $P<0.01$ , \*\*\* $P<0.0001$ .




**Supplementary Figure 3. Outline of HFD mouse experiments.** Timeline of experiment for 12-week old male CD-1 (outbred) and C57BL/6J (inbred) mice fed a HFD or defined control diet. **a** CD-1 mice were fed a HFD and given daily intraperitoneal injections (IP) of MOTS-c (0, 5, or 15 mg/kg/day) from Day 0. Treadmill running tests were performed on Day 7 (Supplementary Fig. 5a) and Day 10 (Fig. 2a-d). Daily MOTS-c injections ceased at Day 16. **b** C57BL/6J mice were started on either a HFD or a defined control diet on Day 0 and continued uninterrupted throughout the experiment. Daily MOTS-c treatment (15 mg/kg; IP) started on Day 14. Treadmill running tests were performed on Day 24 and Day 28 (10 days and 14 days after the start of MOTS-c treatment) (Fig. 2e-h; Supplementary Fig. 5b). Mice were treated daily until Day 56, at which time metabolomics was performed (Fig. 2i).




**Supplementary Figure 4. The effect of MOTS-c on exercise work output.** Based on the treadmill running studies in **a** young CD-1 (Fig. 2a) (n=5 0,5 mg/kg MOTS-c, n=6 15mg/kg MOTS-c) ( $P=0.0346$ ), **b** C57BL/6J (Fig. 2e) (n=8) ( $P=0.0286$  control diet;  $P=0.0122$  HFD), and **c** middle-aged and old C57BL/6N mice (Fig. 3b) (n=10 Middle-Aged mice, n=18 Old MOTS-c and n=19 Old Control) ( $P=0.0479$  Middle-Aged and  $P=0.0005$  Old), total exercise work output was calculated taking into account body weight, acceleration due to gravity, and distance. Data expressed as mean +/- SEM. Two-sided Student's t-test \* $P<0.05$ , \*\*\*\* $P<0.0001$ .



**Supplementary Figure 5. Initial running time of MOTS-c treated young mice. a** Running time of CD-1 mice following seven days of MOTS-c treatment (n=5 for Control and 5 mg/kg MOTS-c, n=6 for 15 mg/kg MOTS-c). MOTS-c (15mg/kg/day) treatment showed a trend towards enhanced running performance. **b** Running time of HFD-fed C57BL/6J mice following 10 days of MOTS-c treatment (n=8) ( $P=0.0229$ ). Data expressed as mean  $\pm$  SEM. Two-sided Student's t-test. \* $P<0.05$




**Supplementary Figure 6. Body composition analysis on MOTS-c treated young mice.** Body composition was measured non-invasively using a time-domain NMR analyzer. **a-c** Young CD-1 mice were treated daily with MOTS-c (0, 5, or 15 mg/kg/day;IP) for 16 days (n=5 control and 5 mg/kg/day MOTS-c, n=6 for 15 mg/kg/day MOTS-c and percent **a** body weight, **b** fat mass ( $P=0.0320$ , 5 vs. 15;  $P=0.0251$ , 0 v 15), and **c** lean muscle mass ( $P=0.0105$ ) were measured. **d-f** C57BL/6J mice either on a HFD or a defined Control Diet and treated daily with MOTS-c (15 mg/kg/day;IP) or saline control (n=8) and percent **d** body weight ( $P<1E-15$ ), **e** fat mass ( $P=0.0119$ ), and **f** lean muscle mass were measured. The dotted line at Day 14 represents the start of MOTS-c treatment. Data expressed at mean  $\pm$  SEM. Significance determined using two-way ANOVA (repeated measures). \* $P<0.05$ , \*\* $P<0.001$ , \*\*\* $P<0.0001$ .





### Supplementary Figure 7. Correlation between body weight and running capacity.

Correlation between body weight (g) and running time (s) was calculated based on Pearson correlation coefficient for **a** young CD-1 (see Fig. 2a), **b** young C57BL/6J (see Fig. 2e), and **c** older C57BL/6N (see Fig. 3b) mice.






**Supplementary Figure 8. The effect of MOTS-c on food intake in young C57BL/6J mice fed a normal or high-fat diet.** Young C57BL/6J mice either on a HFD or a defined control diet were treated daily with MOTS-c (15 mg/kg/day; IP) or saline control (n=8) and food intake was measured. Mice were housed 4 animals/cage and food weight was measured per cage. Food intake is presented per mouse. Two-way ANOVA on 2 cages/group. The dotted line at Day 14 represents the start of MOTS-c treatment. Related to Fig. 2e-i.

**a**Principal Component Loadings - **Fig. 2i****b**Principal Component Loadings - **Fig. 3g**



**Supplementary Figure 9. Principal component loadings.** PC loading **a** relevant to Fig. 2i, PC1 PC3 scatter plot with Glycolysis/ Pentose Phosphate Pathway labels and **b** relevant to Fig. 3g, PC1 PC2 scatter plot with Glycolysis and Hydrophobic Amino Acid labels.

**Fig. 3f**





**a**

**by Age**




**b**

**by MOTS-c Treatment**



**Supplementary Figure 10. Alternate presentation of Fig. 3f divided by age and MOTS-c treatment.** P-values derived using two-way ANOVA. **a**  $P=0.0239$ . **b**  $P=0.0083$ .









**Supplementary Figure 12. Metabolomic analysis on sedentary MOTS-c-treated old mice.** Skeletal muscle from sedentary (not treadmill-exercised) old mice (22.5 months) treated daily with MOTS-c (15 mg/kg/day) for 2 weeks (n=10) were subject to metabolomics and analyzed using PCA.




### Pathways (GSEA/GO\_Biological Process)



**Supplementary Figure 13. Gene expression analysis on skeletal muscle from exercised MOTS-c-treated old mice.** RNA-seq was performed on skeletal muscles from MOTS-c-treated old mice. Balloon plots of biological processes derived from Gene Set Enrichment Analysis (GSEA) using the Gene Ontology (Biological Process) database at a false discovery rate (FDR) < 15% (n=6).




**Supplementary Figure 14. Rotarod and Y-Maze tests in MOTS-c treated old mice.** Middle-aged (14 mo.) and old (24 mo.) mice (n=10 middle-aged mice; n=17 old MOTS-c and n=19 old Control) were treated daily with MOTS-c (15 mg/kg/day;IP) and subject to **a** a rotarod test ( $P=0.000442$ , MA Control vs. Old Control,  $P=0.000008$ , MA MOTS-c vs. Old MOTS-c,  $P=0.000003$ , MA Control vs. MA MOTS-c, and  $P=0.0000002$ , Old Control vs. Old MOTS-c) and **b** y-maze test. Data expressed as mean  $\pm$  SEM. Two-sided Student's t-test. \*\*\* $P<0.0001$ .




**Supplementary Figure 15. Total Physical Activity in MOTS-c treated old mice.** Total movement [horizontal and vertical movement (XYZ-axis)] of MOTS-c treated **a** middle-aged (14 mo.) and **b** old (24 mo.) mice were continuously measured using metabolic cages throughout the day for three days ( $n=4$ ). **c** The sum of all measured movements is shown. **d-f** The procedure was repeated on the same mice after 6 months of LLII MOTS-c treatment ( $P=0.0029$ , Old Control vs. Old MOTS-c,  $P=0.026$ , Middle-Aged Control vs. Old MOTS-c,  $P=0.000013$ , Middle-Aged Control vs. Old Control). Data expressed as mean  $\pm$  SEM of three 24-hour acquisition cycles. Two-sided Student's t-test.  $*P<0.05$ ,  $**P<0.01$ ,  $***P<0.0001$ .






**Supplementary Figure 16. MOTS-c-dependent circadian fuel selection old mice.** Respiratory Exchange Ratio (RER) measurements in LLII MOTS-c-treated, or control, old mice (30 mo.; n=4). Shaded region represents daytime (light cycle) ( $P=0.00004$ ). Data expressed as mean  $\pm$  SEM of three 24-hour acquisition cycles. Two-way ANOVA (repeated measures).



**Supplementary Figure 17. MOTS-c-dependent glycolytic rate in lipid-stimulated mouse myoblasts.** C2C12 mouse myoblasts were treated with MOTS-c (10uM) or saline control in nutrient-limited media (n=11 BSA baseline, n=12 palmitate addition). Real-time glycolytic flux determined by the extracellular acidification rate was measured using the XF96 Seahorse bioanalyzer. Prior to the start of the assay, nutrient-deprived cells were given either BSA alone or palmitate bound to BSA (palmitate-BSA) to determine the capacity to metabolize fatty acids. Data expressed as mean  $\pm$  SEM. Two-Way ANOVA. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .


signed  
enrichment



Pval  
(-Log10)



## Pathways (GO\_BP)



**Supplementary Figure 18 Gene expression analysis on MOTS-c-treated mouse myoblasts under metabolic stress.** RNA-seq was performed on C2C12 myoblasts following 48 hours of GR/SD with MOTS-c (10uM) treatment only once initially (n=6). Balloon plots of biological processes derived from Gene Set Enrichment Analysis (GSEA) using the Gene Ontology (Biological Process) database at a false discovery rate (FDR) < 15% (n=6).